Using intravascular ultrasound to improve dialysis access for patients with end-stage renal disease
Official title: Role of Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
Run by Boston Medical Center · NCT04399941 · Data updated 2026-11-12
This study is testing if using a special ultrasound can help doctors find problems with blood vessels in patients on dialysis to improve their treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 85 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Boston Medical Center Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | August 3, 2021 |
| Main results expected | June 2029 |
| Study ends | December 2029 |
| Registry record updated | October 1, 2026 |
| Trial ID | NCT04399941 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with end-stage renal disease who are currently receiving hemodialysis and experiencing dialysis access malfunction.
✕Probably not a fit
Patients who are not on hemodialysis or do not have a dialysis access malfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of intravascular ultrasound (IVUS) as a diagnostic tool for central venous stenosis (CVS) in patients with end-stage renal disease who are on hemodialysis. Patients experiencing dialysis access malfunction will undergo a diagnostic fistulogram, and the study aims to compare the information obtained from IVUS with traditional venography. By providing more detailed imaging, IVUS may enhance the understanding of vascular conditions affecting dialysis efficacy. The goal is to improve patient outcomes by potentially identifying issues that standard methods may miss.
Why it matters
Potential benefit: If successful, this approach could lead to better management of dialysis access issues, improving the quality of life for patients with end-stage renal disease.
How similar studies have gone: While the use of IVUS in this context is relatively novel, similar imaging techniques have shown promise in other vascular conditions, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ESRD (end stage renal disease) patients at BMC (Boston Medical Center) * Receiving hemodialysis * Has a dialysis access malfunction * Undergoing a diagnostic fistulogram for the dialysis access malfunction Exclusion Criteria: * None
Where it's running
-
Boston Medical Center
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Vipul Chitalia, MD PhD — Boston Medical Center
- Study coordinator: Vipul Chitalia, MD PhD
- Email: vipul.chitalia@bmc.org
- Phone: 617 638 7330
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ribupatide PK in People with Kidney Impairment
This study tests how a single shot of ribupatide behaves in the body for people with severe kidney problems compared to those with normal kidney function.
-
Intradiay dialysis exercise to improve posture in adults with end-stage kidney disease
This study tests whether a 12-week supervised exercise program done during dialysis can improve posture in adults on maintenance hemodialysis.
-
Pumpkin seed oil for people on hemodialysis
This study tests whether taking pumpkin seed oil daily for 3 months helps reduce inflammation and improve-related lab markers in people with end-stage kidney disease on dialysis.
-
Porcine thymokidney transplant for end-stage renal disease
This study tests whether a GalKO porcine thymokidney transplant can keep kidney function without dialysis in adults with end-stage kidney disease who are unlikely to get a standard donor kidney soon.
-
How inflammatory diseases change the way your body handles medicines.
This study will see if inflammatory conditions like type 2 diabetes, IBD, or end-stage kidney disease change how common medicines are processed and increase the chance of side effects.
-
CRISPR-edited donor kidney transplant to reduce rejection risk
This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.